Wick Capital Partners’s CorMedix CRMD Stock Holding History

Wick Capital Partners’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-74,973	Closed	-$318K	–	81
2024 Q1	$318K	Sell	74,973 -44,000	-37%	-$153K	0.31%	34
2023 Q4	$447K	Buy	118,973 +82,988	+231%	+$286K	0.19%	46
2023 Q3	$133K	Buy	35,985 +11,535	+47%	+$45.9K	0.07%	63
2023 Q2	$96.9K	Sell	24,450 -30,400	-55%	-$150K	0.06%	49
2023 Q1	$227K	Buy	+54,850	New	+$224K	0.13%	58
2022 Q3	–	Sell	-114,697	Closed	-$461K	–	53
2022 Q2	$461K	Buy	+114,697	New	+$426K	0.32%	34

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wick Capital Partners's CRMD Position: Q2 2024 in Review

Wick Capital Partners sold out of CorMedix (CRMD) in Q2 2024, closing a stake of 74,973 shares — an estimated $318K sold.

Wick Capital Partners first reported a position in CRMD in Q2 2022 and held it in 6 quarters. The position peaked at $461K in Q2 2022. 99 funds tracked by Wall St. Rank hold CRMD as of Q2 2024.

Wick Capital Partners reported no remaining CorMedix position as of Q2 2024 after selling out during the quarter.
Wick Capital Partners sold 74,973 CorMedix shares in Q2 2024, an estimated $318K.
Wick Capital Partners first reported a position in CorMedix in Q2 2022 and held it in 6 quarters.
Wick Capital Partners's CorMedix position peaked at $461K in Q2 2022.
99 funds tracked by Wall St. Rank held CorMedix as of Q2 2024.

Based on Wick Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.